Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06

被引:30
作者
Hanks, GE
Buzydlowski, J
Sause, WT
Emami, B
Rubin, P
Parsons, JA
Russell, AH
Byhardt, RW
Earle, JD
Pilepich, MV
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[2] Amer Coll Radiol, Philadelphia, PA USA
[3] LDS Hosp, Salt Lake City, UT USA
[4] Washington Univ, St Louis, MO 63130 USA
[5] Univ Rochester, Rochester, NY 14627 USA
[6] Univ Pittsburgh, Ctr Hlth, Pittsburgh, PA 15260 USA
[7] Mercy Gen Hosp, Sacramento, CA USA
[8] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[9] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[10] C McAuley Hlth Ctr, Ann Arbor, MI USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 40卷 / 04期
关键词
node-positive prostate cancer; radiation therapy; 10-year outcomes;
D O I
10.1016/S0360-3016(97)00921-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study was conducted to see what fraction of prostate cancer patients with biopsy-proven nodes are free of cancer 10 years after radiation treatment, Methods and Materials: RTOG protocol #75-06 included 90 patients with biopsy-proven pelvic nodal involvement treated with radiation. They have been continuously follow-up since treatment, When feasible, current prostate-specific antigen (PSA) levels have been solicited from patients clinically cancer-free (no evidence of disease, NED) at 10 years, to confirm cure, Results: The 10-year survival was 29%, the 10-year clinical NED survival 7%, PSA levels were obtained in 2 of 5 10-year clinical NED patients, they were both less than 0.8 ng/ml, The 2 proven cures were both clinical stage T-3, Gleason Score 6 and 8, and had 2 and 1 positive nodes, respectively, Multivariate analysis showed Gleason sum was significantly associated with clinical survival without disease, Conclusion: A small fraction of node-positive patients are cured at 10-year follow-up by radiation therapy (2 of 90 with PSA +3 of 90 by clinical endpoints), Innovative treatment programs should be directed at node-positive patients in an effort to improve the fraction cured. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:765 / 768
页数:4
相关论文
共 21 条
[11]  
2-K
[12]  
LEE RJ, 1994, UROLOGY, V43, P640
[13]   EVALUATION OF SERUM PROSTATE-SPECIFIC ANTIGEN VELOCITY AFTER RADICAL PROSTATECTOMY TO DISTINGUISH LOCAL RECURRENCE FROM DISTANT METASTASES [J].
PARTIN, AW ;
PEARSON, JD ;
LANDIS, PK ;
CARTER, HB ;
POUND, CR ;
CLEMENS, JQ ;
EPSTEIN, JI ;
WALSH, PC .
UROLOGY, 1994, 43 (05) :649-659
[14]   PROGNOSTIC FACTORS IN CARCINOMA OF THE PROSTATE - ANALYSIS OF RTOG STUDY 75-06 [J].
PILEPICH, MV ;
KRALL, JM ;
SAUSE, WT ;
JOHNSON, RJ ;
RUSS, HH ;
HANKS, GE ;
PEREZ, CA ;
ZINNINGER, M ;
MARTZ, KL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (03) :339-349
[15]   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 [J].
Pilepich, MV ;
Caplan, R ;
Byhardt, RW ;
Lawton, CA ;
Gallagher, MJ ;
Mesic, JB ;
Hanks, GE ;
Coughlin, CT ;
Porter, A ;
Shipley, WU ;
Grignon, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1013-1021
[16]  
Pinover WH, 1996, CANCER-AM CANCER SOC, V77, P1334, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1334::AID-CNCR17>3.0.CO
[17]  
2-2
[18]   INFLUENCE OF RADIOTHERAPY ON NODE-POSITIVE PROSTATE-CANCER TREATED WITH ANDROGEN ABLATION [J].
SANDS, ME ;
POLLACK, A ;
ZAGARS, GK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (01) :13-19
[19]   MANAGEMENT OF STAGE-D1 ADENOCARCINOMA OF THE PROSTATE - THE JOHNS-HOPKINS EXPERIENCE 1974 TO 1987 [J].
STEINBERG, GD ;
EPSTEIN, JI ;
PIANTADOSI, S ;
WALSH, PC .
JOURNAL OF UROLOGY, 1990, 144 (06) :1425-1432
[20]   COMBINED HORMONAL AND RADIATION-THERAPY FOR LYMPH NODE-POSITIVE PROSTATE-CANCER [J].
WHITTINGTON, R ;
MALKOWICZ, SB ;
BARNES, MM ;
BRODERICK, GA ;
VANARSDALEN, K ;
DOUGHERTY, MJ ;
WEIN, AJ .
UROLOGY, 1995, 46 (02) :213-219